Blood Clot Testing Device for Surgery Now Class II Approved
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying a special blood test device used during surgery as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on May 9, 2025, and could save time and money for makers and users of these devices.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Detailed study and testing requirements for manufacturers
Manufacturers must provide detailed design verification and validation, including precision studies, performance across the claimed measurement range, interferent testing, specimen stability, and multisite clinical studies. The rule requires multisite clinical testing at a minimum of three external sites and allows contrived specimens only to the extent of 10 to 20 percent of testing when needed.
Device moved to Class II (special controls)
The FDA officially classified the coagulation system for measuring whole blood viscoelastic properties in perioperative patients as Class II (special controls). This classification is effective May 9, 2025 and was applicable March 12, 2019. FDA says this reduces regulatory burdens and will enhance patients' access to the technology.
De Novo gives a predicate for future devices
Because FDA classified this device through the De Novo process, it can serve as a predicate for future devices of the same type, allowing other sponsors to use the less-burdensome 510(k) process instead of De Novo or premarket approval. FDA says this change can reduce regulatory burdens and save time and money for device makers.
Labeling limits on diagnostic claims
The device's labeling must say the device results are not intended to be the sole basis for a patient diagnosis. Unless specific clinical outcome studies are done and acceptable to FDA, labeling must also state the device has not been evaluated to guide blood product use or to guide medication use.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08150, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microbial Nucleic Acids by Fluorescence In Situ Hybridization in Clinical Specimens
The FDA is officially classifying a special device that detects and identifies tiny germs in patient samples using a cool glowing technique called FISH as a Class II device, meaning it’s safe and effective with some special rules. This change helps get these innovative tools to patients faster by cutting down red tape. The new rules took effect on May 9, 2025, and mainly affect companies making or using these devices in healthcare.
Next: 2025-08169, Safety Zone; Fireworks Displays Within the Fifth Coast Guard District; The Wharf, Washington, DC
On June 7, 2025, from 8 p.m. to 10 p.m., the Coast Guard will block off part of the Washington Channel near The Wharf in DC for a fireworks show to keep everyone safe on the water. Boats can’t enter or pass through this area unless they get special permission, so boaters should plan ahead. This temporary safety zone helps make sure the fireworks event is fun and accident-free without any extra costs to the public.